Show simple item record

Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma : the multi-country, cross-sectional SABINA III study

dc.contributor.authorBateman, Eric D
dc.contributor.authorPrice, David
dc.contributor.authorWang, Hao-Chien
dc.contributor.authorKhattab, Adel
dc.contributor.authorSchonffeldt, Patricia
dc.contributor.authorCatanzariti, Angelina
dc.contributor.authorvan der Valk, Ralf J.P.
dc.contributor.authorBeekman, Maarten J.H.I.
dc.date.accessioned2022-10-21T23:07:08Z
dc.date.available2022-10-21T23:07:08Z
dc.date.issued2022-05-05
dc.identifier200022507
dc.identifier050787b2-9530-4ba6-8d97-acbbd33accbc
dc.identifier34561293
dc.identifier85126130182
dc.identifier.citationBateman , E D , Price , D , Wang , H-C , Khattab , A , Schonffeldt , P , Catanzariti , A , van der Valk , R J P & Beekman , M J H I 2022 , ' Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma : the multi-country, cross-sectional SABINA III study ' , European Respiratory Journal , vol. 59 , no. 5 . https://doi.org/10.1183/13993003.01402-2021en
dc.identifier.issn0903-1936
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19221
dc.descriptionData sharing Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Acknowledgements Editorial support was provided by Michelle Rebello, PhD, CMPP, of Cactus Life Sciences (part of Cactus Communications, Mumbai, India) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). This support was fully funded by AstraZeneca. Support statement AstraZeneca funded the study; was involved in the study design, protocol development, study conduct and statistical analysis; and was given the opportunity to review the manuscript before submission. AstraZeneca also funded medical writing support. All authors had full access to all the data, wrote the report and accept responsibility for its publication.en
dc.format.extent13
dc.format.extent3200236
dc.language.isoeng
dc.relation.ispartofEuropean Respiratory Journalen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectasthmaen
dc.subjectglobalen
dc.subjectpublic healthen
dc.subjectprescriptionen
dc.subjectshort acting β2-agonisten
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleShort-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma : the multi-country, cross-sectional SABINA III studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1183/13993003.01402-2021
dc.identifier.vol59en
dc.identifier.iss5en


Files in this item

Thumbnail
Name:
Perez_etal_ACSC_Methanol_Dehyd ...
Size:
3.967Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record